LiCAR

LiCAR is presented in the supplied research summary as a light-switchable CAR platform relevant to the review's topic of optical control of T cell signaling. It serves as an example of optically controlled CAR-T activity.

LiCAR is presented in the supplied research summary as an optogenetic split CAR platform for light-switchable control of CAR-T cells. It is relevant to spatial and temporal regulation of therapeutic T-cell activity.

Implementation requires engineered CAR constructs with optical control elements. The abstract itself does not provide the exact build requirements.

The supplied evidence supports that LiCAR requires an engineered CAR-T construct with optical control logic and a compatible illumination approach. The abstract itself does not specify the photoreceptor components.

It addresses the need for remote or light-dependent control of CAR activation.

It is positioned as a way to make CAR-T activity externally controllable in space and time, which is relevant to safety and precision in adoptive T-cell therapy.

The provided evidence does not establish broad therapeutic performance, manufacturability, or delivery solutions.

The provided review abstract does not establish that LiCAR alone solves durable tumour clearance or solid-tumour resistance. It also does not specify comparative limitations versus other optogenetic CAR systems.

The supplied research summary identifies OptoCAR and opto-ligand-TCR as nearby optical-control alternatives.

Nearby named alternatives in the supplied evidence include optoCAR, light-inducible CAR expression systems using LINTAD or WW-LINTAD, and TamPA-Cre-based gating approaches.